Embedded Files
Breakthroughs
We're committed to transforming patient care through groundbreaking biotechnology. With four novel molecules in our pipeline, we're poised to deliver life-changing therapies that set new standards in healthcare.
Pipeline
August 8, 2024
Compound:
Indication:
Status:
Description:
AspiNex™
Inflammation and Cancer
AspiNex™ is a novel acetylating agent targeting NF-kB, a key regulator of inflammatory responses and cancer progression.
AspiCys™
Oxidative Stress and Inflammation
AspiCys™ is a promising new drug candidate using the “thiol-switch” mechanism to modulate oxidative stress and inflammatory pathways.
NaproSalix™
Cancer and Autoimmune Diseases
NaproSalix™ is a competitive inhibitor of Dihydrofolate Reductase, a critical enzyme in DNA synthesis and repair, making it a potential candidate for cancer and autoimmune disease treatments.
NaproPax™
Drug Delivery Enhancement
NaproPax™ is a drug candidate designed to increase absorption through the cell membrane, enhancing the efficacy and bioavailability of therapeutic agents.
Google Sites
Report abuse